Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Fenebrutinib for Relapsing Multiple Sclerosis
Recruiting1 awardPhase 3
Pasadena, California
This trial will test whether fenebrutinib can help treat relapsing MS by reducing disability progression and relapse rate, compared to teriflunomide. If the results are positive, participants will have the option to continue taking fenebrutinib in an extension phase.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.